Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1993-09-16
1996-12-10
Kim, Kay K. A.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 5, 435 771, 435 772, 435238, 435184, 4352402, 514314, 514317, 514440, 514431, 514289, 514358, 546168, 546192, 546207, 546229, G01N 33573, A61K 31445, A61K 3144, A61K 3147
Patent
active
055830005
ABSTRACT:
Non-peptide, protease-binding compounds are described as useful in the detection, labelling, and inhibition of retroviral proteases. Aryl piperidinyl derivatives and other compounds related in structure have been found to be HIV-1 and HIV-2 protease-binding compounds.
REFERENCES:
patent: 4880779 (1989-11-01), Gallaher
patent: 4916122 (1990-04-01), Chu et al.
patent: 5095021 (1992-03-01), Zipplies et al.
Furth et al (1991) "Inhibition of HIV Protease with Non-Peptide Derivatives of Haloperidol", Fourth Chemical Congress of north America, NY, NY, USA, Aug. 25-30, 1991, Abstr.
De Camp et al, "Structure-Based Inhibition of HIV-1 Protease Activity And Viral Infectivity", in Structure and Function of the Aspartic Proteinases, Dunn, ed., published 1991 by Plenum Press, pp. 489-492.
L. Ratner, et al. "Complete nucleotide sequence of the AIDS virus, HTLV-III," Nature 323:277-284 (1985).
T. J. McQuade, et al. "A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle Maturation," Science 247:454-457 (1990).
H. P. Schnebli and N. J. Braun, "Proteinase inhibitors as drugs," (1986) Elsevier Science Publishers BV.
J. J. Blumenstein, et al. "Synthetic Non-Peptide Inhibitors of HIV Protease," Biochem. and Biophys. Res. Comm. 163:980-987 (1989).
K. Moelling, et al. "In vitro inhibition of HIV-1 proteinase by cerulenin," FEBS Letters 261:373-377 (1990).
N. A. Roberts, et al. "Rational Design of Peptide-Based HIV Proteinase Inhibitors," Science 248:358-361 (1990).
R. Pal, et al. "Processing of the structural proteins of human immunodeficiency virus type 1 in the presence of monensin and cerulein," Proc. Natl. Acad. Sci. 85:9283-9286 (1988).
W. G. Farmerie, et al. "Expression and Processing of the AIDS Virus Reverse Transcriptase in Escherichia coli," Science 236:305-308 (1987).
C. Debouck, et al. "Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor," Proc. Natl. Acad. Sci. 84:8903-8906 (1987).
N. E. Kohl, et al. "Active human immunodeficiency virus protease is required for viral infectivity," Proc. Natl. Acad. Sci. 85:4686-4690 (1988).
M. A. Navia, et al. "Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1," Nature 337:615-620 (1989).
R. Lapatto, et al. "X-ray analysis of HIV-1 proteinase at 2.7 .ANG. resolution confirms structural homology among retroviral enzymes," Nature 342:299-302 (1989).
A. Wlodawer, et al. "Conserved Folding in Retroviral Proteases: Crystal Structure of a Synthetic HIV-1 Protease," Science 245:616-621 (1989).
S. Seelmeier, et al. "Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A," Proc. Natl. Acad. Sci. 85:6612-6616 (1988).
P. L. Darke, et al. "Human Immunodeficiency Virus Protease," J. Bio. Chem. 264:2307-2312 (1989).
T. D. Meek, et al. "Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease," Proc. Natl. Acad. Sci. 86:1841-1845 (1989).
L. H. Pearl and W. R. Taylor, "A structural model for the retroviral proteases," Nature 329:351-354 (1987).
A. G. Tomasselli, et al. "Substrate Analogue Inhibition and Active Site Titration of Purified Recombinant HIV-1 Protease," Biochemistry 29:264-269 (1990).
T. D. Meek, et al. "Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues," Nature 343:90-92 (1990).
S. Pichuantes, et al. "Recombinant HIV2 Protease Processes HIV1 Pr53.sup.gag and Analogous Junction Peptides in Vitro," J. Bio. Chem. 265:13890-13898 (1990).
R. L. DesJarlais, et al. "Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease," Proc. Natl. Acad. Sci 87:6644-6648 (1990).
M. L. Moore, et al. "Peptide Substrates and Inhibitors of the HIV-1 Protease," Biochem. and Biophys. Res. Comm. 159:420-425 (1989).
T. Maniatis, et al. "Molecular Cloning, A Laboratory Manual," (Cold Spring Harbor Press NY (1982).
L. Babe' et al., "HIV1 Protease: Bacterial Expression, Purification and Characterization," Protein and Pharm. Eng. pp. 71-88 (1990).
G. B. Dreyer, et al., "Inhibition of human immunodeficiency virus 1 protease in vitro: Rational design of substrate analogue inhibitors," Proc. Natl. Acad. Sci. USA vol. 86 pp. 9752-9756 (Dec. 1989).
H. Toh, et al., "Close structural resemblance between putative polymerase of a Drosophila transposable genetic element 17.6 and pol gene product of Moloney murine leukaemia virus" EMBO J. vol. 4 5:1267-1272 (1985).
M. D. Power, et al., "Nucleotide Sequence of SRV-1, a Type D Simian Acquired Immune Deficiency Syndrome Retrovirus," Science 231:1567-1572 (Mar. 1986).
AIDS Research and Reference Reagent Program Catalog (Jan. 1991 Catalog) NIH Pub. No. 91-1536.
Alvarez Juan C.
Bab e Lilia M.
Caldera Patricia S.
Craik Charles S.
De Voss James
Kim Kay K. A.
The Regents of the University of California
LandOfFree
Protease-binding compounds and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protease-binding compounds and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease-binding compounds and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-423376